Comparative Pharmacology
Head-to-head clinical analysis: QTERN versus ZITUVIMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QTERN versus ZITUVIMET.
QTERN vs ZITUVIMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
QTERN is a fixed-dose combination of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Dapagliflozin reduces renal glucose reabsorption, increasing urinary glucose excretion. Saxagliptin increases incretin hormones, enhancing insulin secretion and decreasing glucagon levels.
ZITUVIMET (sitagliptin/metformin) combines sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases incretin levels (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon secretion; and metformin, a biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
One tablet orally twice daily; each tablet contains dapagliflozin 10 mg and saxagliptin 5 mg.
Zituvimet is a fixed-dose combination tablet containing sitagliptin 50 mg and metformin hydrochloride 500 mg or 1000 mg. Usual adult dose: one tablet (50 mg sitagliptin / 500 mg metformin) twice daily with meals, or one tablet (50 mg sitagliptin / 1000 mg metformin) twice daily with meals, based on patient's current metformin dose. Maximum daily dose: sitagliptin 100 mg, metformin 2000 mg. Route: oral, with meals to reduce gastrointestinal side effects.
None Documented
None Documented
Terminal half-life approximately 5 hours; supports twice-daily dosing.
Metformin: ~6.2 hours (prolonged in renal impairment); sitagliptin: ~12.4 hours (allows once-daily dosing).
Fecal (59% unchanged) and renal (42% unchanged, primarily via tubular secretion).
Renal: 90% (metformin unchanged), biliary/fecal: 10% (sitagliptin).
Category C
Category C
Antidiabetic Combination
Antidiabetic Combination